SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 21st, 2013 • Feinberg Family Trust • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2013, between Vermillion, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
STOCKHOLDERS AGREEMENTStockholders Agreement • June 21st, 2013 • Feinberg Family Trust • In vitro & in vivo diagnostic substances • New York
This STOCKHOLDERS AGREEMENT (the “Agreement”) is made as of May 13, 2013 by and among Vermillion, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), Oracle Partners, LP and Oracle Ten Fund Master, LP (together, “Oracle”), Jack W. Schuler (“Schuler” and together with Oracle, the “Principal Purchasers”) and the other purchasers named in the Purchase Agreement (as defined below) (collectively, the “Purchasers”).
JOINT FILING AGREEMENTJoint Filing Agreement • June 21st, 2013 • Feinberg Family Trust • In vitro & in vivo diagnostic substances
THIS JOINT FILING AGREEMENT is entered into as of June 17, 2013, by and among the parties signatories hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the shares of the common stock, par value $0.001 per share, of Vermillion, Inc., a Delaware corporation, is, and any amendment thereafter signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
